1. Home
  2. SPHL vs AKTX Comparison

SPHL vs AKTX Comparison

Compare SPHL & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

HOLD

Current Price

$2.33

Market Cap

6.1M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

N/A

Current Price

$5.72

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPHL
AKTX
Founded
2002
N/A
Country
Singapore
United States
Employees
71
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
6.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SPHL
AKTX
Price
$2.33
$5.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
9.4K
45.5K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.12
52 Week High
$25.11
$6.46

Technical Indicators

Market Signals
Indicator
SPHL
AKTX
Relative Strength Index (RSI) 40.98 73.57
Support Level $2.18 $0.27
Resistance Level $3.11 $6.46
Average True Range (ATR) 0.21 0.53
MACD 0.00 -0.03
Stochastic Oscillator 15.59 72.51

Price Performance

Historical Comparison
SPHL
AKTX

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: